Evidence map›Paper›PMID 42165099›Full record

ReviewClinical and translational medicine2026

Cancer: A bioelectric disease?

Celine Desoyer, Roko Šupe, Sahar Ghorbanpour, Debkalpa Goswami, Mina Khalaj, Nazanin Karami, Dagmar Brislinger, Charlotte A E Hauser, Christian Baumgartner

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Celine DesoyerInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0009-0003-8918-057X
Roko ŠupeInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.
Sahar GhorbanpourInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0000-0001-5614-5215
Debkalpa GoswamiInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0000-0002-6698-0027
Mina KhalajInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0009-0002-2694-6569
Nazanin KaramiInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0009-0008-6991-7382
Dagmar BrislingerDepartment of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.ORCID 0000-0002-7319-5377
Charlotte A E HauserInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0000-0001-8251-7246
Christian BaumgartnerInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0000-0002-3763-5195

Funding

TU Graz Open Access Publishing Fund
6 · The paper itself

Abstract

Cancer progression is driven by coordinated alterations in signalling networks that regulate proliferation, plasticity, metabolism and therapeutic response. Although genetic and epigenetic mechanisms are well characterised, there is an increasing body of evidence that suggests bioelectric signalling constitutes an additional integrative regulatory layer in tumour biology. In diverse experimental systems, malignant cells consistently exhibit depolarised transmembrane potentials (V

Indexed as

Membrane PotentialsNeoplasmsAnimalsHumansSignal Transductionbioelectric biomarkersbioelectric signallingcancer bioelectricityion channels in cancermembrane potential (Vm)precision oncologytumour progression and stemnesstumour‐treating fields

Identifiers

PMID42165099
PMCPMC13239130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.